RSS

National Institute for Health and Care Excellence (NICE)

Chief executive of the National Institute for Health and Care Excellence (NICE) Sir Andrew Dillon has announced he will step down from the role next year. Read more

News

A lack of clinical evidence is preventing clinicians from being able to prescribe cannabis-based medicines, an NHS review has found. Read more

News

The National Institute for Health and Care Excellence (NICE) has recommended shorter courses of antibiotics in an effort to cut down on overuse and the risk of antibiotic resistant infections. Read more

News

Pharmaceutical companies will be paid to develop new drugs for resistant infections in a new incentive scheme launched by the NHS. Read more

News

Innovative cancer drugs are taking longer to get to patients due to delays in clinical trials and regulatory red tape, new data shows. Read more

News

The National Institute for Health and Care Excellence (NICE) has given a positive recommendation for Crysvita (burosumab) to be used in the treatment of X-linked hypophosphataemia (XLH) in children and young people with growing bones. Read more

News

Here we count down the top five tweets from @EPM_magazine that have gained the most impressions this week, taken from Twitter analytics. Read more

News

The National Institute for Health and Care Excellence (NICE) has published its positive guidance for the first selective interleukin (IL)-23 inhibitor to treat moderate to severe plaque psoriasis. Read more

News

A delegate of experts from the North of England will be showcasing their excellence in tackling antimicrobial resistance (AMR) to an international conference in Boston, Massachusetts, USA. Read more

News

Here we count down the top five tweets from @EPM_magazine that have gained the most impressions this week, taken from Twitter analytics. Read more

News

The National Institute for Health and Care Excellence (NICE) has issued its final appraisal determination (FAD) to Janssen recommending Tremfya (guselkumab) for treatment of adults with moderate to severe plaque psoriasis. Read more

News

The Medicines and Healthcare products Regulatory Agency (MHRA) has implemented changes to the licence for valproate medicines — Epilim, Depakote and generics used to treat epilepsy and bipolar disorder — in the interest of public safety. Read more

News

Following a series of papers, published in The Lancet and featuring contributions from Professor Martin Underwood of Warwick Medical School, the NHS has published recommended changes to the treatment of low back pain. Read more

News

London-based scientists have found a new blood test that may be able to quickly predict if a female patient is responding to the breast cancer drug, palbociclib, earlier that is possible with currently available tests. Read more

Technology

A final appraisal determination (FAD) has been issued by the National Institute for Health and Care Excellence (NICE), recommending routine NHS use of avelumab for the treatment of adults in England, Wales and Northern Ireland with mMCC Read more

News

Breast cancer treatment, eribulin (Halaven), will still be accessible to patients with advanced metastatic breast cancer despite recent guidance by the National Institute of Health and Care Excellence (NICE), according to Eisai. Read more

News

Here we count down the top five tweets from @EPM_magazine that have gained the most impressions this week, taken from Twitter analytics. Read more

News

The National Institute for Health and Care Excellence (NICE) has issued a final appraisal decision (FAD) recommending the reimbursement of lenvatinib (Lenvima) for the treatment of differentiated thyroid cancer. Read more

News

The National Institute for Health and Care Excellence (NICE) has published a Final Appraisal Determination (FAD) recommending tivozanib as a first-line treatment option for advanced renal cell carcinoma (aRCC) in line with its licensed indication Read more

News

NHS England has revealed that thousands of patients have benefited from the new CDF and as a result of discounts it has secured on eight treatments, savings of around £140 million should be generated over the course of the next five years Read more

News